Literature DB >> 24613255

Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.

Gábor Cserni1, András Vörös2, Inta Liepniece-Karele3, Simonetta Bianchi4, Vania Vezzosi4, Dorthe Grabau5, Anna Sapino6, Isabella Castellano6, Peter Regitnig7, Maria Pia Foschini8, Vassiliki Zolota9, Zsuzsanna Varga10, Paulo Figueiredo11, Thomas Decker12, Cornelia Focke12, Janina Kulka13, Handan Kaya14, Angelika Reiner-Concin15, Isabel Amendoeira16, Grace Callagy17, Emer Caffrey17, Jelle Wesseling18, Clive Wells19.   

Abstract

The Ki67 labelling index (LI - proportion of staining cells) is widely used to reflect proliferation in breast carcinomas. Several cut-off values have been suggested to distinguish between tumours with low and high proliferative activity. The aim of the current study was to evaluate the distribution of Ki67 LIs in breast carcinomas diagnosed at different institutions by different pathologists using the method reflecting their daily practice. Pathologists using Ki67 were asked to provide data (including the LI, type of the specimen, receptor status, grade) on 100 consecutively stained cases, as well as details of their evaluation. A full dataset of 1709 carcinomas was collected from 19 departments. The median Ki67 LI was 17% for all tumours and 14% for oestrogen receptor-positive and HER2-negative carcinomas. Tumours with higher mitotic counts were associated with higher Ki67 LIs. Ki67 LIs tended to cluster around values ending with 5 or 0 both in cases where the values were obtained by counting the proportion of stained tumour cell nuclei and those where the values were obtained by estimation. On the basis of the distribution pattern described, some currently used Ki67 LI cut off values are not realistic, and it is proposed to select more realistic values ending with 0 or 5.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Ki67; Proliferation

Mesh:

Substances:

Year:  2014        PMID: 24613255     DOI: 10.1016/j.breast.2014.02.003

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  28 in total

1.  Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer.

Authors:  Balázs Ács; Lilla Madaras; Kristóf Attila Kovács; Tamás Micsik; Anna-Mária Tőkés; Balázs Győrffy; Janina Kulka; Attila Marcell Szász
Journal:  Pathol Oncol Res       Date:  2017-04-11       Impact factor: 3.201

2.  Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.

Authors:  András Vörös; Erika Csörgő; Bence Kővári; Péter Lázár; Gyöngyi Kelemen; Orsolya Rusz; Tibor Nyári; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

3.  Fruit peel polyphenols demonstrate substantial anti-tumour effects in the model of breast cancer.

Authors:  Peter Kubatka; Andrea Kapinová; Martin Kello; Peter Kruzliak; Karol Kajo; Desanka Výbohová; Silvia Mahmood; Radovan Murin; Tischlerová Viera; Ján Mojžiš; Anthony Zulli; Martin Péč; Marián Adamkov; Monika Kassayová; Bianka Bojková; Nadežda Stollárová; Dušan Dobrota
Journal:  Eur J Nutr       Date:  2015-05-01       Impact factor: 5.614

4.  Oregano demonstrates distinct tumour-suppressive effects in the breast carcinoma model.

Authors:  Peter Kubatka; Martin Kello; Karol Kajo; Peter Kruzliak; Desanka Výbohová; Ján Mojžiš; Marián Adamkov; Silvia Fialová; Lucia Veizerová; Anthony Zulli; Martin Péč; Dagmar Statelová; Daniel Grančai; Dietrich Büsselberg
Journal:  Eur J Nutr       Date:  2016-02-23       Impact factor: 5.614

5.  Quality assurance trials for Ki67 assessment in pathology.

Authors:  M Raap; S Ließem; J Rüschoff; A Fisseler-Eckhoff; A Reiner; S Dirnhofer; R von Wasielewski; H Kreipe
Journal:  Virchows Arch       Date:  2017-05-11       Impact factor: 4.064

6.  Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

Authors:  Joseph J Fantony; Lauren E Howard; Ilona Csizmadi; Andrew J Armstrong; Amy L Lark; Colette Galet; William J Aronson; Stephen J Freedland
Journal:  Biomark Med       Date:  2018-06-15       Impact factor: 2.851

7.  Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium.

Authors:  Gábor Cserni
Journal:  Virchows Arch       Date:  2018-03-28       Impact factor: 4.064

8.  Antineoplastic effects of clove buds (Syzygium aromaticum L.) in the model of breast carcinoma.

Authors:  Peter Kubatka; Sona Uramova; Martin Kello; Karol Kajo; Peter Kruzliak; Jan Mojzis; Desanka Vybohova; Marian Adamkov; Karina Jasek; Zora Lasabova; Pavol Zubor; Silvia Fialova; Svetlana Dokupilova; Peter Solar; Martin Pec; Katarina Adamicova; Jan Danko; Mariusz Adamek; Dietrich Busselberg
Journal:  J Cell Mol Med       Date:  2017-05-19       Impact factor: 5.310

9.  Breast carcinoma subtypes show different patterns of metastatic behavior.

Authors:  István Artúr Molnár; Béla Ákos Molnár; Laura Vízkeleti; Krisztina Fekete; Judit Tamás; Péter Deák; Csilla Szundi; Borbála Székely; Judit Moldvay; Stefan Vári-Kakas; Marcell A Szász; Balázs Ács; Janina Kulka; Anna-Mária Tőkés
Journal:  Virchows Arch       Date:  2017-01-19       Impact factor: 4.064

10.  Ki-67 and caspase expression in breast carcinoma: does variance in locational sampling exist?

Authors:  Filinte Deniz; Kaymakci Dilek; Mollamemisoglu Hande; Ugurlu M Umit; Kaya Handan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.